
CLAIMS

1. Use of a compound in the manufacture of a medicament for the treatment of lung adenocarcinoma in a patient, wherein the compound is compound 1:



Compound 1


or a pharmaceutically acceptable salt thereof; and
wherein the lung adenocarcinoma is SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer.

2. The use according to claim 1, wherein the compound is the (L)- or (D)-malate salt of compound 1.

3. The use according to claim 1 or claim 2, wherein the compound is administered as a pharmaceutical composition additionally comprising a pharmaceutically acceptable carrier, excipient, or diluent.

4. The use according to any preceding claim, wherein the compound is administered post-cisplatin and/or gemcitabine treatment; or wherein the compound is administered post-carboplatin treatment; or wherein the compound is administered post-carboplatin and/or gemcitabine treatment; or wherein the compound is administered post-cisplatin and/or carboplatin treatment; or wherein the compound is administered post-docetaxel treatment; or wherein the compound is administered post-crizotinib treatment; or wherein the compound is administered post-crizotinib and/or gemcitabine treatment; or wherein the compound is administered post-crizotinib and/or gemcitabine and/or docetaxel treatment; or wherein the compound is administered post-cisplatin and/or gemcitabine and/or docetaxel treatment.


5. Use of a compound in the manufacture of a medicament for the treatment of a ROS1 fusion-positive non-small cell lung cancer in a patient, wherein the compound is compound 1:



Compound 1

or a pharmaceutically acceptable salt thereof;
wherein the lung cancer is SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer.

6. Use of a compound in the manufacture of a medicament for inhibiting or reversing the progress of cancer mediated by ROS1 kinase in a mammal, wherein the compound is compound 1:



Compound 1

or a pharmaceutically acceptable salt;
wherein the cancer is SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer.


7. The use according to claim 6, wherein the compound is administered as a pharmaceutical composition comprising compound 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

8. The use according to claim 7, wherein the pharmaceutical composition is administered daily for more than 3 months.

9. The use according to claim 7 or claim 8, wherein the pharmaceutical composition is administered at a dosage of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 65, 70, 75, 80, 85, 90, or 95 mg/day.

10. The use according to any of claims 7-9, wherein detection of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using a FISH, CISH or SISH assay; or wherein detection of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using any form of genome PCR, direct sequencing, PCR sequencing, RT-PCR or similar assay; or wherein detection of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using an antibody which specifically binds to SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion polypeptide or a fragment thereof.

11. Use of a compound in the manufacture of a medicament for the diagnosis and treatment of a patient, wherein the patent has a NSCLC tumor and the tumor is identified as SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive NSCLC, wherein the compound is compound 1:



Compound 1

or a pharmaceutically acceptable salt thereof, and wherein the compound is administered with at least one pharmaceutically acceptable carrier.

12. The use according to claim 11, wherein identification of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using a FISH, CISH or SISH assay; or wherein identification of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using any form of genome PCR, direct sequencing, PCR sequencing, RT-PCR or similar assay; or wherein identification of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using an antibody which specifically binds to SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion polypeptide or a fragment thereof.

13. The use according to any preceding claim, wherein the compound produces at least one therapeutic effect selected from the group consisting of reduction in size of a tumor, reduction in metastasis, complete remission, partial remission, stable disease, increase in overall response rate, and a pathologic complete response.

14. The use according to any preceding claim, wherein compound 1 is administered orally once daily as its free base or the malate salt as a capsule or tablet containing up to 100 mg of compound 1, preferably containing 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg of compound 1.